News of Note—Mylan now recalling 104 lots of valsartan medications


> Mylan, after initially recalling just 15 lots of valsartan-based drugs that it says were tainted by a carcinogen, has now expanded its consumer-level voluntary nationwide recall to include all 104 lots of valsartan-containing products within expiry. Release

> Boehringer Ingelheim has sold its synthetic API plant to Japan’s AGC which will now have its first FDA-approved facility in Europe in the CDMO business. Release

> After putting South Korea’s Barox on its import alert list, the FDA has issued a warning letter to the OTC repackager. Warning letter

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> The FDA has issued a Form 483 to Gadea Biopharma in Leon, Spain, after an inspection of the sterile drug manufacturer lacked some of the basic processes for producing drugs. Form 483

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.